Villalobos-Acosta CP, Plascencia-Gómez EC, Romano-Mazzotti L, Pavía-Ruz N

Idioma: Español
Referencias bibliográficas: 46
Paginas: 314-324
Archivo PDF: 154.03 Kb.

RESUMEN

Introducción. Después de la introducción del tratamiento antirretroviral altamente activo (TARAA), la sobrevida y la calidad de vida de las personas infectadas por el virus de inmunodeficiencia humana (VIH), incluyendo los niños y adolescentes, han mejorado sustancialmente.
Métodos. El presente estudio se realizó en una cohorte de niños infectados por VIH, menores de 18 años de edad, que asistieron a la Clínica de Inmunodeficiencias/VIH del Hospital Infantil de México Federico Gómez de abril de 1989 a diciembre de 2008. De los expedientes clínicos se obtuvieron: datos sociodemográficos, eventos infecciosos, hospitalizaciones y defunciones.
Resultados. Se incluyeron 202 pacientes infectados por el VIH con o sin TARAA. El promedio de edad al diagnóstico de síndrome de inmunodeficiencia adquirida fue de 37.3 meses. La transmisión perinatal fue la más frecuente con 96%. Al diagnóstico de VIH la mayoría cursaba con enfermedad avanzada. La tasa de incidencia de infecciones oportunistas antes del diagnóstico fue de 30.2/100 pacientes/año, mientras que posterior al TARAA disminuyó a 3.3; 95% de los pacientes que recibieron TARAA tuvieron una sobrevida de 10 años en promedio.
Conclusiones. Con la administración del TARAA se observó disminución de eventos infecciosos, hospitalizaciones y mortalidad en la población estudiada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Centers for Diseases Control: unexplained immunodeficiency and opportunistic infections in infants. MMWR Morb Mortal Wkly Rep. 1982; 31: 665-7.

2. UNAIDS. Report on the global HIV/AIDS epidemic; 2007 December.

3. Secretaría de Salud. Dirección General de Epidemiología. Registro Nacional de Casos de SIDA. Datos al 14 de Noviembre del 2008. México: Centro Nacional para la Prevención del VIH/SIDA (CENSIDA); 2008.

4. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988: 319: 889-96.

5. McKinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991; 324: 1018-25.

6. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991; 324: 137-44.

7. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis. 1996; 174: 16­25.

8. Kline MW, Culnane M, van Dyke RB, et al. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics. 1998; 101: 214-20.

9. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 1995; 96 (2 Pt 1): 247-52.

10. Paediatric European Network for Treatment of AIDS (PENTA). A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS. 1998; 12: F151-60.

11. McKinney RE, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine­lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. 1998; 133: 500-8.

12. Resino S, Resino R, Micheloud D, et al. Long- term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1­infected children: 6 years of follow-up. Clin Infect Dis. 2006; 42: 862-9.

13. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001; 345: 1522-8.

14. Gona P, van Dyke R, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006; 296: 292-300.

15. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J. 2003; 22: 635-41.

16. Gibb DM, Duong T, Tookey PA, et al. National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003; 327: 1019.

17. McConnell MS, Byers RH, Frederick T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989­2001. J Acquir Immune Defic Syndr. 2005; 38: 488-94.

18. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007; 45: 918-24.

19. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004; 39: 725-31.

20. Sánchez JM, Ramos-Amador JT, Fernández-de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003; 22: 863-7.

21. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000; 284: 190-7.

22. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362: 22-9.

23. Fleishman JA, Hellinger FJ. Recent trends in HIV-related inpatient admission, 1996-2000. Epidemiol Soc Sci. 2003; 34: 102-10.

24. Danker WM, Lindsey JC, Levin MJ, et al. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001; 20: 40-8.

25. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS. Defining opportunistic illnesses, 1992-1997. MMWR Surveill Summ. 1999; 48: 1-22.

26. Ledergerber B, Egger M, Erard V, Weber R, et al. AIDS-Related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study. JAMA. 1999; 282: 2220-6.

27. Kourtis AP, Bansil P, Posner SF, Jonson C, et al. Trends in Hospitalizations of HIV-infected children and adolescents in the United States: Analysis of data from the 1994-2003 nationwide inpatient sample. Pediatrics. 2007; 120: e236-e43.

28. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the perinatal AIDS. Collaborative Transmission Study, 1986-2004. Pediatrics. 2007; 120: 100-9.

29. Candiani TMS, Pinto J, Araújo CA, Carvalho IR, et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil. Cad Saude Publica. 2007; 23: S414-S23.

30. Pérez GLF, Morán MA, Santos PJI. Síndrome de inmunodeficiencia adquirida (SIDA) en pediatría. Informe del primer caso en México. Bol Med Hosp Infant Mex. 1986; 43: 729.

31. Centers for Diseases Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994; 43: 1-10.

32. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997; 175: 1029-38.

33. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998; 279: 756-61.

34. Coonor EW, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331: 1173-80.

35. Wade NA, Zielinsky MA, Butsashvili M, et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr. 2004; 36: 1075-82.

36. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV1 infected women and prevention of perinatal HIV-transmission. J Acquir Immune Defic Syndr. 2002; 29: 484-94.

37. Wade NA, Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005; 38: 87-95.

38. Ortiz-Ibarra FJ, Cashat-Cruz M. Prevención de la transmisión perinatal del VIH: Una meta alcanzable. Bol Med Hosp Infant Mex. 2003; 60: 643-54.

39. Ylitalo N, Brogly S, Hughes M, Nachman S, et al. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med. 2006; 160: 778-87.

40. Pallella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338: 853-60.

41. Resino S, Larrú B, Bellón JM, Resino R, et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infect Dis. 2006; 6: 107.

42. Puthanakit T, Aurpibul L, Oberdorfer, Akarathum N, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007; 44: 599-604.

43. Nachman S, Gona P, Dankner W, Weinberg A, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005; 115: e488-e94.

44. Fallo AA, Dobrzanski-Nisiewics W, Sordelli N, Cattaneo MA, et al. Clinical and epidemiologic aspects of human immunodeficiency virus-1-infected children in Buenos Aires, Argentina. Int J Infect Dis. 2002; 6: 9-16.

45. Spira R, Lepage P, Msellati P, van de Perre, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics. 1999; 104: e56.

46. Muñoz HR, Villalobos ACP, Pavía RN. SIDA en pediatría. En: Estrategias globales para la prevención y tratamiento de la transmisión del VIH/SIDA: Resultados de las intervenciones. México: Ed. Elsevier; 2007. p. 75-89.